Head-To-Head Comparison: Adicet Bio (NASDAQ:ACET) and Acumen Pharmaceuticals (NASDAQ:ABOS)

Adicet Bio (NASDAQ:ACET) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares Adicet Bio and Acumen Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80 million	($14.90)	-0.57
Acumen Pharmaceuticals	N/A	N/A	-$121.33 million	($1.86)	-1.37

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Adicet Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Adicet Bio and Acumen Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1	1	5	1	2.75
Acumen Pharmaceuticals	1	0	3	0	2.50

Adicet Bio presently has a consensus price target of $48.80, suggesting a potential upside of 474.12%. Acumen Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 162.47%. Given Adicet Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Adicet Bio is more favorable than Acumen Pharmaceuticals.

Insider and Institutional Ownership

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Adicet Bio and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-80.35%	-65.44%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Adicet Bio beats Acumen Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.